Related Experiment Video
Updated: Jan 27, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
Claire Gourzones1, Céline Bellanger2, Sylvain Lamure3
1IGH, CNRS, University of Montpellier, 34000 Montpellier, France. cgourzones@gmail.com.
Background:
Multiple myeloma (MM) is the second most common hematological cancer after lymphoma. It is characterized by the accumulation of clonal malignant plasma cells within the bone marrow. The development of drug resistance remains a major problem for effective treatment of MM. Understand the mechanisms underlying drug resistance in MM is a focal point to improve MM treatment.
Methods:
In the current study, we analyzed further the role of redox imbalance induction in melphalan-induced toxicity both in human myeloma cell lines (HMCLs) and primary myeloma cells from patients.
Results:
We developed an in-vitro model of short-term resistance to high-dose melphalan and identified that pretreatment with physiological concentration of GSH protects HMCLs from melphalan-induced cell cycle arrest and cytotoxicity. We validated these results using primary MM cells from patients co-cultured with their bone marrow microenvironment. GSH did not affect the ability of melphalan to induce DNA damages in MM cells. Interestingly, melphalan induced reactive oxygen species, a significant decrease in GSH concentration, protein and lipd oxydation together with NRF2 (NF-E2-related factor 2) pathway activation.
Conclusions:
Our data demonstrate that antioxidant defenses confers resistance to high dose melphalan in MM cells, supporting that redox status in MM cells could be determinant for patients' response to melphalan.
Related Concept Videos
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Bioavailability Study Design: Single Versus Multiple Dose Studies
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Defenses Against Pathogens and Herbivores

